Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
Grommes C, Tun H, Rosenthal A, Lunning M, Ramchandren R, Regales L, Zhao W, Lane M, Wang C, von Roemeling R, Isufi I, Leslie L, Nowakowski G. Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2023, 142: 4497. DOI: 10.1182/blood-2023-189746.Peer-Reviewed Original ResearchInterleukin-1 receptor-associated kinase 4Non-Hodgkin lymphomaFMS-like tyrosine kinase 3Bid dose levelToll-like receptorsDose escalationBTK inhibitorsNHL patientsDose levelsAcceptable long-term safety profileRefractory non-Hodgkin lymphomaLong-term safety profileB-cell non-Hodgkin lymphomaBruton tyrosine kinase inhibitorsBTK inhibitor resistanceContinuous oral dosingMurine PDX modelPhase 2 doseRelapsed/Refractory Non-Hodgkin LymphomaMedian treatment durationOpen-label trialRefractory hematologic malignanciesBlood-brain barrierPreliminary efficacy dataNovel oral inhibitor